Schonfeld Strategic Advisors’s Aligos Therapeutics ALGS Stock Holding History
Bought
Maintained
Sold
Other funds holding ALGS
BBA
Schonfeld Strategic Advisors's ALGS Position: Q3 2026 in Review
Schonfeld Strategic Advisors opened a new position in Aligos Therapeutics (ALGS) in Q3 2026: 181,880 shares worth $1.02M. The stake represents ﹤0.01% of the portfolio and ranks #1556 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in ALGS as recently as Q1 2022.
Schonfeld Strategic Advisors first reported a position in ALGS in Q4 2020 and has held it in 3 quarters since. 36 funds tracked by Wall St. Rank hold ALGS as of Q3 2026.
- Schonfeld Strategic Advisors held 181,880 shares of Aligos Therapeutics worth $1.02M as of Q3 2026.
- Aligos Therapeutics was a new Schonfeld Strategic Advisors position in Q3 2026.
- Aligos Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q3 2026, its #1556 holding.
- Schonfeld Strategic Advisors first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 3 quarters since.
- 36 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.